
News|Videos|October 30, 2026
PharmTech Weekly Roundup—October 30, 2026: Formulation, AI, and NAMs at AAPS PharmSci 360
Author(s)Susan Haigney
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Advertisement
Advertisement
This week on PharmTech.com, coverage from AAPS PharmSci 360 in New Orleans showed that evidence must be trustworthy, whether it comes from an artificial intelligence (AI) model, an organ-on-chip, or a platform formulation. From formulation AI and amorphous solid dispersions (ASDs) to a new FDA framework for gene editing, the common thread was that faster development still depends on data regulators can verify.
Related to this article

How confident is the bio/pharma workforce heading into 2027? PharmTech wants to find out, and we need your input.

Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.

Cole and Jaenisch explain where pharma should keep manual checks, how to vet AI skills in hires, and why self-taught AI risks GMP.

This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.

Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.

Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.

EU GMP Annex 22: AI Pulse Check panelists say most manufacturers aren’t ready, static AI models likely stay central, and local AI deployment grows.
Advertisement
Advertisement

